With all the uncertainty of COVID-19, we hope you are safe and in good health. Ozgene is still here to meet your research needs.

IAPs limit activation of RIP kinases by TNF receptor 1 during development.

 Back to publications

2012

The EMBO journal 2012 Feb 10. doi: 10.1038/emboj.2012.18. [Epub ahead of print]

IAPs limit activation of RIP kinases by TNF receptor 1 during development.

M Moulin;H Anderton;AK Voss;T Thomas;WW Wong;A Bankovacki;R Feltham;D Chau;WD Cook;J Silke;DL Vaux

La Trobe Institute for Molecular Science, La Trobe University, Victoria, Australia.

Service type: Double targeting

Abstract

Inhibitor of apoptosis (IAP) proteins cIAP1, cIAP2, and XIAP (X-linked IAP) regulate apoptosis and cytokine receptor signalling, but their overlapping functions make it difficult to distinguish their individual roles. To do so, we deleted the genes for IAPs separately and in combination. While lack of any one of the IAPs produced no overt phenotype in mice, deletion of cIap1 with cIap2 or Xiap resulted in mid-embryonic lethality. In contrast, Xiap(-/-)cIap2(-/-) mice were viable. The death of cIap2(-/-)cIap1(-/-) double mutants was rescued to birth by deletion of tumour necrosis factor (TNF) receptor 1, but not TNFR2 genes. Remarkably, hemizygosity for receptor-interacting protein kinase 1 (Ripk1) allowed Xiap(-/-)cIap1(-/-) double mutants to survive past birth, and prolonged cIap2(-/-)cIap1(-/-) embryonic survival. Similarly, deletion of Ripk3 was able to rescue the mid-gestation defect of cIap2(-/-)cIap1(-/-) embryos, as these embryos survived to E15.5. cIAPs are therefore required during development to limit activity of RIP kinases in the TNF receptor 1 signalling pathway.

View Publication